Since the emergence of the biopharmaceutical industry in the 1980's, Escherichia coli, has played an important role in the industrial production of recombinant proteins and plasmid DNA for therapeutic use. Currently, advanced biopharmaceutical products, including rationally designed recombinant proteins and viral-vector gene therapies, offer unprecedented promise for the long-term management, and even cure of disease. As such, E. coli remains an important production host for the biopharmaceutical industry. This review provides insight into the industrially relevant strain engineering approaches used to enhance both the quantity and quality of these therapeutic products.
INTRODUCTION
Despite the diverse mix of expression platforms currently in use in academia and the biotechnology industry, Escherichia coli remains one of the most used microbial production hosts for the generation of various therapeutic biological products. Historically, following the emergence of the biopharmaceutical industry in the 1980's, E. coli dominated as the main production organism used in >60% of cases for biopharmaceutical protein production (Huang, Lin and Yan 2012) . This was due in part to a combination of a short doubling time, ability to grow to high cell densities and the relatively simple scale-up procedure. Nowadays, mammalian cell lines, most notably CHO (Chinese Hamster Ovary) cells hold the number one position for protein production platforms, due their suitability to generate glycosylated proteins. However, E. coli is still the organism of choice to express heterologous proteins for therapeutic use, with around 30% of all approved therapeutic proteins being produced in this host (Overton 2014; Sanchez-Garcia et al. 2016) . Furthermore, with the recent clinical success seen with a number of gene therapy-based products, there has been resurgence in the biopharmaceutical industry for the use of E. coli for the production of bacterial plasmid DNA (pDNA). Plasmid DNA is now considered a biopharmaceutical in its own right, particularly for applications in gene therapy and DNA vaccination.
Although a number of reviews exist describing various aspects of E. coli strain engineering to support the enhanced production of recombinant proteins (Rosano and Ceccarelli 2014; Baeshen et al. 2015; Marschall, Sagmeister and Herwig 2016; Negrete and Schiloach 2017) and, to a lesser extent, pDNA (Prather et al. 2003; Gonçalves et al. 2012) , only a limited number discuss the role that strain engineering plays in supporting the quality of the therapeutic molecule produced, and none, to our knowledge, that cover both classes of biopharmaceuticals. In this mini-review, we will provide an overview of the role that strain engineering of E. coli is playing within the biopharmaceutical industry, focusing on the regulatory quality aspects required for these therapeutically relevant classes of molecule.
Biopharmaceutical utilisation of E. coli
Escherichia coli remains the most widely used, cost-effective microbial 'factory' for recombinant protein production (RPP), and for the generation of pDNA. It is considered the main workhorse for the production of non-glycosylated recombinant proteins in the biopharmaceutical industry, used for the generation of onethird of the approved protein therapeutics (Terpe 2006) . Due to its widespread use in molecular biology and biopharmaceutical applications, coupled with its cost-effectiveness and scalability, E. coli was also selected as the main host for therapeutic pDNA production. However, for use within the biopharmaceutical industry there remain important regulatory quality aspects ( Fig. 1 ) to consider when using E. coli for the production of therapeutic molecules.
Strain characterisation and engineering for RPP
Escherichia coli K-12 strains and their derivatives (DH1, DH5α, MG1655, RV308 and W3110) are the most widely used strains by the biotechnology industry. However, K-12 strains are known to produce high levels of acetate, an undesirable by-product formed during anaerobic fermentation, resulting in detrimental effects on cell growth and RPP (more detail can be found in Huang, Lin and Yan 2012; Waegeman and De Mey 2012) . Alternatively, E. coli B strains are commonly used due to their low acetate accumulation, allowing high concentrations of glucose to be used as carbon source (Sørensen and Mortensen 2005) . Escherichia coli BL21 and its parental strain B834 were originally selected for the expression of T7 RNA polymerase due to a defective ompT gene that encodes an outer membrane protease capable of cleaving a site in the T7 RNA polymerase (Studier and Moffatt 1986) . Today, E. coli BL21 is the most commonly used strain for RPP. Derivative strains where the T7 RNA polymerase has been located under the control of an inducible promoter, such as the lactose (lac) or the arabinose promoter (ara), have been generated for use in combination with T7 expression system vectors (Fernandez and Hoeffler 1999; Wycuff and Matthews 2000) . Different cultivation conditions have been used with a focus on achieving increased biomass and product yield (Striedner et al. 2003; Marisch et al. 2013a) ; however, the interplay between host cell metabolism and RPP remains poorly understood. Although these approaches work, limited system information can be gained from growth characteristics of specific hosts. Recently, a comparative analysis of E. coli K and B strains generated detailed genomic information on global strain characteristics and transcriptional and translational patterns, extending the specific host knowledge and identifying potential host gene targets for strain engineering (Marisch et al. 2013b) . This remains an active area of research for RPP within the biopharmaceutical industry.
Although increasing host biomass coupled to RPP yield is an important economic driver for the biopharmaceutical industry, consideration must also be given to ensure that the recombinant protein produced and the production system are of sufficient quality for therapeutic usage, meeting tight compliance and regulatory standards (Sanchez-Garcia et al. 2016) . These quality factors include minimisation of E. coli host cell contaminants and maximisation of correctly folded biologically active protein. However, certain host limitations, relating to the causation of adverse immunogenic responses in humans (Fig. 1) , and the inability to perform certain post-translational modifications can hinder the potential of E. coli to overexpress recombinant proteins destined for therapeutic use.
Obtaining correctly folded biologically active protein

Protein targeting approaches
Escherichia coli cells, like other Gram-negative bacteria, possess an inner and outer membrane that divides the organism into two main compartments: the cytoplasm and the periplasm, both being potential targets for RPP. The cytoplasm is the most common choice for the production of recombinant proteins, as often leads to high titers of correctly folded protein. However, the successful production of recombinant proteins in a soluble form will depend on the host cell's capability and on the total metabolic load imposed on the cells during RPP (Sahdev, Khattar and Saini 2008) . Alternatively, recombinant proteins can be targeted to the periplasmic space or the extracellular environment when disulphide bonds are required for correct folding. There are three main pathways used for protein translocation in E. coli: the SecB dependent, the SRP mediated and the TAT Figure 2 . Periplasmic protein translocation pathways and disulphide bond formation in E. coli (Adapted from Baneyx and Mujacic 2004; Lobstein et al. 2012) . SecBdependent translocation pathway (A). The majority of the protein intended to be translocated to the periplasm is directed to the SecB-dependent pathway. The trigger factor (TF) binds to nascent chains as they emerge from the ribosome. Subsequently, polypeptides are transferred to DnaK or SecB, which prevents its premature folding. SecB delivers the precursor protein to SecA, which initiates its translocation through the SecYEG translocon complex. SRP-mediated pathway (B). The majority of the proteins with highly hydrophobic signal peptides (green) or transmembrane segments are recognised by SRP, which delivers the nascent chains to FtsY and to the SecYEG complex. TAT translocation pathway (C). Fully folded or partially folded precursor proteins with signal peptides bearing the twin-arginine motif (yellow) are translocated by the TAT pathway, through the TatABC complex. DSB oxidative pathway (I). Cysteine pairs in protein containing disulphide bonds are introduced by DsbA, while DsbB helps to main DsbA in an oxidised form. DSB isomerisation pathway (II). DsbC catalyses the isomerisation of incorrectly formed disulphide bonds, as part of the DsbC is maintained in a reduced form by DsbD. Representation of engineered redox pathways for disulphide bond formation in the cytoplasm (III). Dotted arrows represent disrupted protein interactions resulted from the deletion of trxB and gor genes. Recombinant proteins can be either reduced by Grx1, which in turn is reduced by a mutated AhpC * , or oxidised by Trx1. Disulphide bonds can be isomerised to a correctly folded state by cytoplasmic DsbC.
translocation pathways (Fig. 2) ; with the SecB-dependent pathway being the most exploited route for RPP (Mergulhao, Summers and Monteiro 2005) . Secreted proteins are synthesised in the cytoplasm with an amino-terminal signal peptide as a precursor protein (Choi and Lee 2004) . Precursor proteins can be targeted to the Sec translocon by SecB once the protein has been translated (co-and post-translational translocation), or by the signal recognition particle (SRP), as soon as the nascent chain exits the ribosome tunnel (co-translational translocation) ( Fig. 2A and B ). Both translocation routes converge at the SecYEG complex, where SecA acts as a receptor for SRP and SecB. SecB prevents premature folding, maintaining the protein in a translocation-competent state (Papanikou, Karamanou and Economou 2007) . A preferred option for recombinant proteins that fold too quickly in the cytoplasm is the SRP-mediated pathway as proteins that tend to aggregate or fold prematurely may fail to translocate through the SecB-dependent pathway (Lee and Jeong 2013). As exemplified above, efficient E. coli 'secretion'-based systems form the basis for a range of industrial biopharmaceutical production platforms; however, many target proteins fail to translocate to the periplasm because the standard Sec pathway export machinery is only capable of transporting unfolded proteins (Natale, Bruser and Driessen 2008) . In contrast, the Twin Arginine Translocation (TAT) pathway is able to export fully folded proteins, plus co-factor substrates up to 150 kDa in size ( Fig. 2C) (Paschke 2006) . However, to date this system has not been used for industrial production, due to low product yields, partly due to the low abundance of the TAT apparatus when compared to the Sec system (Tullman-Ercek et al. 2007 ). Overexpression of the TatABC proteins from a second plasmid can boost export of a heterologous target protein (Matos et al. 2012) , but the use of dual plasmid systems has clear disadvantages for industrial applications. Recently, Browning et al. (2017) detailed the development of the TatExpress strains, where the tac promoter has been inserted upstream of the TatA promoter in the chromosome. TatExpress strains, either with W3110 or BL21 backgrounds, exhibited enhanced export of hGH and singlechain antibody fragments, used as model therapeutic proteins, when compared with wild type E. coli strains.
Production routes for disulphide-bonded proteins
A frequent route for production of recombinant protein requiring disulphide bonds is within the periplasm, an approach used by Genentech for the commercial production of their secondgeneration Nutropin/somatropin hGH product (Gray et al. 1985) . Periplasmic production eliminates the need for refolding because proteins can usually form their correct set of disulphide bonds in the oxidising environment of the bacterial periplasm. In fact, in wild-type E. coli, stably disulphide-bonded proteins are only found in the cell envelope where disulphide formation and isomerisation is catalysed by a set of thiol-disulphide oxidoreductases known as the Dsb proteins (DsbA, DsbB, DsbC and DsbD) (Baneyx and Mujacic 2004) . In the periplasmic space, DsbA, oxidises secreted proteins and is able to engage nascent protein substrates as they emerge from the translocon (Fig. 2I ). Incorrectly introduced disulphide bonds can be addressed by DsbC and DsbG, which act by reducing incorrect disulphide bonds and shuffling them to correct conformation (Fig. 2II) . Their functions are efficiently maintained by their respective redox partners, DsbB reoxidises DsbA, while DsbC and DsbG in turn are oxidised by DsbD (Gleiter and Bardwell 2008; Zhang, Chou and Moo-Young 2011; Hatahet, Boyd and Beckwith 2014) .
Currently, in order to produce properly folded, disulphidebonded recombinant proteins, such as antibody-derived products (representing >35% of all therapeutically licensed proteins produced in E. coli), proteins need to be translocated out the cytoplasm into the periplasm. However, other strains have been developed, such as the AD494 and Origami (Novagen, EMD Bioscience, Madison, US) strains that are deficient in trxB and trxB/gor genes respectively, which facilitate disulphide bond formation in the cytoplasm (Sørensen and Mortensen 2005) . Also commercially available are the 'SHuffle' (New England Biolabs, Ipswich, Massachusetts, US) strains, which in addition to trxB and gor mutations, also overexpress DsbC in the cytoplasm (Fig. 2III ). DsbC is a disulphide bond isomerase, with chaperone activity, which assists the reshuffling and correct pairing of cysteine residues. This extends the potential for more complex correctly folded recombinant proteins to be produced (Lobstein et al. 2012; Hatahet, Boyd and Beckwith 2014) . As a further refinement, a water-soluble DsbB variant and DsbA were co-expressed in the cytoplasm and were able to efficiently catalyse de novo disulphide formation with a wide range of model proteins (Mizrachi et al. 2017) . Nevertheless, low industrial applicability has been reported for 'oxidising strains', as results are often unpredictable in terms of protein yield (de Marco 2013 ).
An alternative is the co-expression of a catalyst of disulphide bond formation (Ervp1, inverted DsbB or VKOR) in combination with a disulphide bond isomerase (DsbC or PDI), the CyDisCo (Paras Biopharmaceuticals Finland Oy, Kurkenlatie, Finland) protein production technology (Cytoplasmic Disulphide bond formation in E. coli), thereby allowing the formation of disulphide bonds in the presence of intact reducing pathways in the cytoplasm (Gaciarz et al. 2016) .
Folding assistance
The overexpression of recombinant proteins may result in the accumulation of misfolded proteins in inclusion bodies (IBs). Indeed, the first recombinant protein to gain approval, human insulin produced in E. coli, involved the recovery of intracellular IBs that required protein refolding (Chance and Frank 1993) . A costeffective alternative to protein refolding is the co-expression of molecular chaperones along with the recombinant protein of interest to facilitate protein folding and minimise protein aggregation (see review for details, Gupta and Shukla 2016) . Coexpression of the GroEL-GroES complex, improved the solubility of certain proteins that would otherwise form IBs (Nishihara et al. 2000) . Although some approaches have proved useful (reviewed by Baneyx and Mujacic 2004; Kolaj et al. 2009 ), this is not always the case. Indeed, overexpression of DnaK-DnaJ-GrpE complex did not consistently enhance solubility, or adversely affected protein yield (reviewed by Martinez-Alonso et al. 2010) .
Accumulation of misfolded proteins is not only limited to the cytoplasm, but can also occur in the cell envelope as a result of temperature increase, oxidative stress or improper formation of disulphide bonds. The primary housekeeping periplasmic protease is DegP, which at low temperatures switches function to that of a chaperone. In contrast with the cytoplasm, the periplasm only contains a single bona fide chaperone, Skp, involved in the capture of unfolded proteins as they emerge from the Sec translocon, assisting the folding and membrane insertion of outer membrane proteins (Sahdev, Khattar and Saini 2008) . Enhancement in the production of an anti-CD20 single-chain variable fragment (scFv) was achieved upon Skp coexpression (Mavrangelos et al. 2001) . Other periplasmic folding modulators have been described that increase the yields of proteins produced in the periplasm, including the overexpression of DsbA and DsbC (Reilly and Yansura 2010) , and the peptidylprolyl isomerases, SurA and FkpA (Baneyx and Mujacic 2004; Huang, Lin and Yan 2012) .
Strain engineering: minimising protease activity
It is well known than E. coli BL21, the main workhorse strain for RPP, is deficient in OmpT and Lon proteases, which are involved in the degradation of heterologous recombinant proteins in E. coli. Furthermore, strains for periplasmic expression have also been engineered to possess, either singly or in combination disruption in genes encoding envelope proteases, including ptr3 (Protease III), htr (DegP), ompT (OmpT) and tsp (Prc), in order to minimise proteolytic degradation of recombinant proteins that are targeted to and accumulate within the periplasm (Champion et al. 2001) . Strains based on these approaches are currently used in the production and commercial manufacturing of Ranibizumab (Lucentis R ) by Genentech. The E. coli 60E4 strain (W3110, fhuA phoA htrA ompT ptr ilv62096 rhaR fucP) was used to produce a humanised monoclonal antibody fragment (Fab) designed to target human vascular endothelial growth factor A (VEGF-A), and approved to treat 'wet' agerelated macular degeneration (AMD) (EMEA 2007). Protease deficient strains, more specifically DegP Prc Spr triple mutants, have been reported to increase Fab yields (Chen et al. 2004 ). An even higher increase has been described when using a combination of folding modulator co-expression, such as DsbC or FkpA, with processes successfully scaled up to over 1000L for the industrial production of multiple Fab proteins (Ellis et al. 2017) . In a further refinement, with the aim to produce biologically active protein and reduce host cell contamination, the biopharmaceutical company Wacker Biotech (Jena, Germany) has developed ESETEC R , an E. coli K-12 derivative strain engineered to secrete correctly folded proteins to the growth medium, reducing process-related impurities, such as host cell DNA and endotoxins. ESETEC R strains have been engineered with a modified outer membrane, possibly resulting from a mutation in the lpp gene, which codes for the major outer membrane lipoprotein (Richter and Koebsch 2017) .
Codon usage in E. coli
Although the above approaches for RPP support industrial application, there remains an inherent probability within E. coli of inserting translational errors into the recombinant protein expressed due to the large number of rare codons present in the heterologous genes (Baeshen et al. 2015) . Codons that are abundant in eukaryotic genes have been found to be rarely used in E. coli (Gustafsson, Govindarajan and Minshull 2004) , with expression of heterologous genes containing these rare codons resulting in translational errors including amino acid substitutions, frame-shift mutations or premature translation termination. In the case of therapeutic protein production, translational errors, even at extremely low levels, can potentially cause adverse immunogenic responses in humans. Recently, an enhanced analytical mass spectrometry technique uncovered a remarkably large pool of error products for a model recombinant protein expressed in E. coli, which depended quantitatively on codon usage in the expression construct. This codon usage dependence was explained, in part, as a function of the composition of the tRNA pool in this organism (Jossé et al. 2017) . Different strategies to avoid the issue of codon bias in E. coli can be employed. One approach involves the modulation of the tRNA pool of E. coli, via co-transformation of strains with a second plasmid carrying a gene encoding the tRNA cognate to the rare codons (Sørensen and Mortensen 2005) , and there are several commercial E. coli strains available (e.g. E. coli Rosetta (DE3)) that use such an approach. However, the preferred approach currently used by biopharmaceutical companies is to synthesise the whole gene sequence based on codon usage, minimising the impact of these rare codons on gene expression.
The importance of expression control
The global market for recombinant protein-based therapeutics continues to rapidly expand. Furthermore, the diversity of products in development is increasing, moving from 'simple' recombinant molecules to every more sophisticated complex protein products. This growth is taking advantage of the diverse number of E. coli production strains and expression approaches that exist. However, fundamentally the balance between productivity and product quality is determined by the complex interplay between processing conditions, host strain, recombinant product and expression system employed. High-level recombinant protein expression, coupled to the presence and continued maintenance of foreign plasmids can rapidly exhaust the metabolic resources, block protein folding and/or protein translocation machinery, all leading to induction of stress responses in the host cell (Glick 1995; Hoffman and Rinas 2004; Sevastsyanovich, Alfasi and Cole 2010) . These responses can ultimately affect product quality and quantity, as it is frequently observed that a reduction of protein expression level correlates to increased end product titres, as host cells are maintained in a productive state for longer.
As such, research has focused on the area of expression tuning, aiming to alleviate the burden that recombinant protein expression has on the host cell. This approach would provide the means to optimally adjust the level of protein expression to accurately match the inherent capacity of the host cell, tuning RPP to a level optimal for protein translation, folding, translocation and maintaining long-term productivity (Sevastsyanovich, Alfasi and Cole 2010) . This can be done at both the process and genetic level. For example, E. coli Tuner strains (Novagen, EMD Bioscience, Madison, US) that are lacY mutants, allow precise control of gene expression by fine tuning of the inducer concentration (Sahdev, Khattar and Saini 2008) , facilitated by uniform entry of the IPTG inducer. These types of applications rely on a small set of protein-based control mechanisms working at the level of transcription initiation.
In a recent development, the ability to obtain a high level of expression control using a dual transcription-translational system offers an alternative means to control recombinant gene expression. The novel tuneable expression system, RiboTite, which operates at both the transcriptional and translational level uses standard inducible promoters and orthogonal riboswitches to control the expression of both bacteriophage T7 RNA polymerase and recombinant genes of interest (Dixon et al. 2010; Morra et al. 2016) . Riboswitches are mostly found in the 5' UTR of bacterial mRNAs (Serganov and Nudler 2013) , where they operate via a number of mechanisms, including translation initiation, transcription termination or mRNA cleavage mechanisms (Roth and Breaker 2009; Breaker 2012; Morra et al. 2016) . Riboswitches function by changing conformation when bound to a specific metabolite, thus regulating expression post-transcriptionally. Dixon et al. (2010) re-engineered the Add-A translational ON riboswitch from Vibrio vulnificus to no longer bind to its cognate metabolite, but instead to the synthetic inducer, PPDA. The E. coli BL21 (IL3) strain was engineered to contain the T7 RNA polymerase under the dual control of both the lac promoter/operator (transcriptional control) and orthogonal riboswitch (translational control) (Fig. 3) . This strain can be combined with any plasmid carrying the recombinant gene of interest under the control of the T7 promoter. Using eGFP as model protein, it was shown that transcriptional and translational induction resulted in a dependent titratable response allowing the system to be tuned to permit dynamic expression control (Morra et al. 2016) . Riboswitch expression tuning is an exciting development to support industrial RPP, although it remains to be seen if it provides the ability to fine tune expression to match that of protein translocation and secretion.
Production of plasmid DNA
Large scale production of pDNA is of increasing industrial importance and challenge to the biopharmaceutical industry. Resurgence in interest for Advanced Therapeutic Medicinal Products, such as genetic medicines and DNA vaccines, demands high (>10 g up to <5 kg) quantities of plasmid products to be produced. Therapeutically, plasmid produced can be used either in the form of naked pDNA facilitating direct clinical use, or as a critical starting material for transient production of viral vectorbased gene therapy products.
For use in biopharmaceutical applications both high plasmid yield and quality must be achieved adhering to tight compliance and regulatory standards (Fig. 1) . As well as the minimisation of E. coli host cell contaminants, the quality factors include the maximisation of correctly conformed plasmid. Plasmids that have open-circle, nicked and linear conformations are considered less effective therapeutically than densely packed, supercoiled pDNA (Hassan, Keshavarz-Moore and Ward 2016) , with the less effective forms being regarded as impurities requiring removal, to specified levels, during plasmid purification.
The characteristics of the host strain have been shown to affect the overall quality of the purified pDNA produced (Yau, Keshavarz-Moore and Ward 2008) . A wide range of E. coli strains (DH5α, DH5, DH1, JM108, SCS1-L and DH10B) have been used routinely in laboratories for plasmid production (Singer, Eiteman and Altman 2009; Borja et al. 2012) . Within the biopharmaceutical industry the main strains used (DH5, DH5α, JM108 and DH1) all belong to the E. coli K-12 class and have been approved by the FDA for the clinical and commercial production of pDNA. These strains contain mutations that facilitate efficient plasmid production, namely endA and recA. Deletion of these specific two genes has been shown to increase plasmid yield and quality (Phue et al. 2008; Yau, Keshavarz-Moore and Ward 2008; Singer, Eiteman and Altman 2009; Gonçalves et al. 2012) , by eliminating non-specific degradation of the plasmid by endonucleases, and minimising recombination and improving plasmid stability, respectively. However, the effects of these mutations appear strain and/or plasmid dependent (Yau, Keshavarz-Moore and Ward 2008) .
Engineering host strains for better plasmid production
The increasing demand for biopharmaceutical pDNA has led to a number of host cell engineering approaches aimed at improving pDNA production (reviewed in Gonçalves et al. 2012) . Desirable phenotypes have been sought with the ability to ferment to high cell density and high plasmid copy number, minimise the generation of plasmid-free cells, decrease the potential to incur genetic alterations to the plasmid, and have compatibility with purification procedures (Eastman and Durland 1998; Yau, Keshavarz-Moore and Ward 2008) . These attempts have focused on manipulating carbon flux through the central metabolism pathways in E. coli. Strain engineering approaches have aimed to enhance energy and reducing power, through the deletion of the pykF/pykA genes, increase flux through the pentose phosphate pathway, and overexpress the rpiA/zwf gene products, to increase synthesis of nucleotide precursors. These approaches along with deletion of the fruR gene, encoding a transcriptional regulator of central carbon metabolism, have been shown to increase the maximum specific growth rate and plasmid production of the engineered strains. However, these strains were subject to specific culture and/or fermentation conditions, and do not readily translate to industrial usage. Furthermore, an extensive investigation into host genetics controlling pDNA quantity and quality in DH5α failed to improved yield (Williams et al. 2009) , highlighting the lack of transferability between strains.
The E. coli B strain BL21 has been suggested as an alternative to the commonly used K strains for pDNA production, due to better growth and metabolic characteristics (Phue et al. 2008) . However, this strain lacks the recA and endA mutations typically found in normal E. coli plasmid production hosts. Phue et al. (2008) engineered these mutations into BL21 and were able to achieve a 90% increase in volumetric yield compared to DH5α. Borja et al. (2012) introduced the recA, deoR, nupG and endA mutations individually or in combination into VH33, high yields were obtained but the percentage of supercoiled plasmid was lower when compared to the more commonly used DH5α host.
Challenge of stability for plasmids containing viral sequences
Plasmid 'instability' is defined as the generation of high levels of open circle plasmid, plasmid loss or structural rearrangement resulting in truncated forms of the plasmid being generated. It is often observed in plasmids containing multiple repeated sequences (Bichara et al. 2000) and sequences prone to form secondary structure (Razin et al. 2001) . Both of these genetic elements are frequently present in plasmids used for the transient production of viral-vector products. Such plasmids are prone to undergo recombination resulting in the loss of the viral DNA sequences, detrimental to manufacturing. As such, overcoming plasmid 'instability' issues remains a key focus for the generation plasmid for viral vector production. Whilst it may be possible to modify plasmid sequences, this is often not feasible as this may impact therapeutic functionality; therefore, alternative strategies to address plasmid instability are required.
Process related approaches, relating to growth rates and temperature shifts, are currently employed widely in the biopharmaceutical industry. However, a number of E. coli strains (Stbl2 (Trinh et al. 1994); Stbl3 (Al-Allaf et al. 2013) ; Stbl4 (Schmidt and Bloom 1999) from Invitrogen (Thermo Fisher Scientific, Waltham, Massachusetts, US); E. coli SURE cells (Razin et al. 2001) from Stratagene (La Jolla, California, US) have been identified that claim to decrease the likelihood of these events occurring. However, these strains have limitations for industrial use due to reduced growth rates and unfavourable genetic backgrounds. Al-Allaf et al. (2013) showed that the production of a plasmid carrying a lentiviral sequence, was severely compromised in a number of E. coli strains, including Stbl2, despite having recA mutations. Interestingly, the same plasmid was successfully produced to high levels in the Stbl3 strain. The genetic reasons for this are unclear; however, the E. coli Stbl3 strain is a derivative of E. coli HB101 and therefore a cross between the wild-type E. coli isolates K-12 and B, whereas the Stbl2 strain was derived solely for an E. coli K-12 isolate. Other strains have been engineered with the generation of reduced genomes; MDS42 is an example of such a strain with a 15% reduction in its genome. This strain has been shown to increase stability of lentiviral plasmids (Chakiath and Esposito 2007) and has the benefit of maintaining good growth profiles.
Strain engineering to support plasmid production for gene therapy applications
Whilst strategies for increasing plasmid yield remain important, other drivers for the biopharmaceutical industry include product safety and cost (Carnes, Hodgson and Williams 2006) . The presence of antibiotic resistance genes is a specific safety issue with regard to gene therapy products. There is increased pressure for the elimination of antibiotic resistance markers, as well as antibiotics in the production of pharmaceutical products (Mignon, Sodoyer and Werle 2015) . It is not only the antibiotic, but the antibiotic resistance gene together with any unnecessary bacterial plasmid DNA that are of concern, due to the potential of gene transfer and the provocation of inflammatory reactions (Yew et al. 2000) . Therefore, there is a clear industrial drive to replace antibiotic resistance selection with an alternative means of plasmid maintenance.
The route to antibiotic gene removal has mainly been accomplished in E. coli by the complementation of auxotrophy, through to systems requiring minimal RNA, tRNA and DNA elements and finally to the almost complete removal of bacterial DNA with the generation of plasmid mini-circles (Oliveira and Mairhofer 2013; Mignon, Sodoyer and Werle 2015; Fig. 4 ). This has resulted in the progressive reduction in both plasmid size and bacterial DNA content.
A number of systems have been developed that in addition to the origin of replication only require a small sequence of DNA that either code for a small RNA molecule or contain an operator binding site. For example, Soubrier et al. (1999) have developed plasmid retention based on pCOR vectors and strains where plasmid is maintained by means of a suppressor tRNA that overcomes the amber mutation within the argE gene.
The murselect and RNAout technologies elegantly allow plasmid retention by RNA/RNA interactions, resulting in the production of gram scale antibiotic free plasmids. They rely on an RNA antisense regulator encoded by the plasmid and a genetically engineered E.coli strain. The murselect technology relies on the control of expression of a repressor protein that in turn controls the transcription of an essential gene (MurA) that encodes an enzyme for the first committed step in peptidoglycan biosynthesis. If MurA is not expressed, then cell wall biosynthesis cannot occur. The system utilises the naturally occurring RNAI-RNAII interaction that allows control of plasmid replication to inhibit the expression of the repressor protein by the inclusion of an RLS (RNAII like sequence) that hybridises to RNAI preventing transcription of the repressor (Mairhofer et al. 2010) . The RNAout plasmid retention system encodes an antisense RNA on the plasmid that is capable of repressing the chromosomally encoded sacB gene (coding for levansucrase). When grown in a sucrose containing growth medium production of sacB is toxic; however, in the presence of the plasmid sacB expression is repressed providing a means for plasmid retention (Williams 2013) .
ORT (operator repressor titration) is an alternative to these RNA-based systems and does not require additional media additives. It is again based on the promoter-operator of an essential gene being regulated by a chromosomally encoded repressor protein. Strains have been developed where the dapD gene (coding for tetrahydrodipicolinate N-succinyltransferase involved with cell wall synthesis) is under the control of the lac promoter-operator together with the lac repressor. The presence of a multicopy plasmid containing a copy of the short (21bp) operator titrates the repressor from the essential gene allowing expression of the dapD gene and hence growth and plasmid maintenance (Cranenburgh et al. 2001) . Plasmids produced using ORT have been produced in gram quantities and used in preclinical and clinical HIV-1 DNA vaccine studies (Oliveira and Mairhofer 2013) .
Plasmid backbone minimisation has been taken further by the generation of mini-circle DNA (Mayrhofer et al. 2008) . For example, strains have been engineered to chromosomally encode inducible recombinases such as the cre recombinase (Biggar et al. 2001) , which allows recombination between plasmid borne loxP sites. This generates mini-circle DNA retaining only a single recombination site. Although these products are likely to further enhance the efficacy of plasmid DNA they are currently difficult to perform at scale.
CONCLUSION
As the production of more complex proteins is required to support rapidly growing therapeutic research areas, and as the gene therapy field continues to emerge and grow, there will be increasing pressure to develop microbial systems that are better able to balance quantity, quality and cost of the production. Furthermore, with the recent developments in the area of systems and synthetic biology (Gardner 2013) , full characterisation of bacterial pathways should enable accurate predictive design. These approaches, when applied to E. coli, will ensure that it remains one of the key organisms of choice utilised in the biopharmaceutical industry for the production of advanced biologics.
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